Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578
Stocks News & Analysis
stocks
Reassuring organic growth for undervalued ASX share
stocks
Big IPOs are enticing but are they good investments?
stocks
This defensive ASX listed REIT offers a 5% yield
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,692.80 | 143.80 | -1.63% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,368.95 | 472.67 | -2.07% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 56,662.47 | 2,781.74 | -4.68% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,592.60 | 137.80 | -1.58% |
| SSE Composite Index | 3,506.50 | 71.12 | -1.99% |